Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00158639 · ClinicalTrials.gov registry record · Phase 3
Electronic Communications and Home Blood Pressure Monitoring
A Phase 3 study of Hypertension, sponsored by Kaiser Permanente.
- Completed
- Registry status
- Phase 3
- Development phase
- 778
- Enrollment target
- 1
- Study location
NCT00158639: Completed Phase 3 study of Hypertension, sponsored by Kaiser Permanente.
NCT00158639 is a Phase 3 study of Hypertension that has completed, run by Kaiser Permanente. The registered enrollment target is 778 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00158639, a Phase 3 study of Hypertension, has completed, sponsored by Kaiser Permanente.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 778 participants
- Enrollment target
- 1
- Study location
Study Summary
The control of blood pressure (BP) for patients with hypertension on medications has been elusive, despite the availability of evidence-based nationally recognized guidelines for treatment and 30 years of research addressing this. At present, less than 50% of patients with known hypertension are adequately controlled. If BP control could be improved, significant decreases in cardiovascular morbidity and mortality would occur. The purpose of this study is to conduct a randomized controlled trial of the effectiveness of the provision of home blood pressure measurement and electronic communications (secure messaging to health care providers) to improve hypertension control.
Conditions Studied
Interventions
- BEHAVIORAL Home BP;secure messaging;pharmaceutical care;
Study Locations (1)
Washington
- Group Health Research Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 778 participants |
| Start Date | 2005-06 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
What the finished NCT00158639 record still lists
NCT00158639 is an interventional study that assigns participants to a tested intervention. The registered 778 participants enrollment target is mid-sized for trials with a published cap, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Home BP;secure messaging;pharmaceutical care; is the first listed.
NCT00158639 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00158639 about?
NCT00158639 is a clinical study titled "Electronic Communications and Home Blood Pressure Monitoring". The control of blood pressure (BP) for patients with hypertension on medications has been elusive, despite the availability of evidence-based nationally recognized guidelines for treatment and 30 years of research addressing this. At present, less than 50% of patients with known hypertension are ade...
What is the current status of trial NCT00158639?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 778 participants. The study started on 2005-06. Estimated completion is 2007-12.
What conditions does trial NCT00158639 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00158639?
The interventions under investigation include: Home BP;secure messaging;pharmaceutical care; (BEHAVIORAL).
Who is sponsoring clinical trial NCT00158639?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00158639 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00158639's enrollment target sits among peer trials
778 90th of 470 higher than 381 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06841679 · 778 participants · Phase 2
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT05642611 · 777 participants · Phase 3
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy
- NCT05046613 · 780 participants
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
- NCT05100862 · 780 participants · Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia